Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Newron Pharmaceuticals S.p.A.

https://www.newron.com/en

Latest From Newron Pharmaceuticals S.p.A.

Masimo’s MightySat Receives First FDA Clearance For OTC Pulse Oximeter

The first clearance from the US Food and Drug Administration for an over-the-counter fingertip pulse oximeter has gone to Masimo's MightySat Medical, which is now available at the company's website.

Approvals Patient Monitoring

Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances

More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.

Scrip Asks Advanced Therapies

Digital Health Roundup: CES Biggest Hits; Apple Versus Masimo; Insulet Recalls Diabetes App

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights interviews with industry leaders in medtech and healthtech and demos of some of the most innovative tech seen at CES 2024 in Las Vegas. Hannah Daniel dives into the latest developments in the intellectual property dispute between Apple and Masimo over blood oxygen sensors in the newer Apple Watch models.

Digital Health Artificial Intelligence

Finance Watch: Three New Funds Bring $1.6bn-Plus For Biopharma Firms Globally

Private Company Edition: TCGX raises $1bn for its second fund, Goldman Sachs’ first fund totals $650m and Panlin’s biopharma fund grows. Also, Apollo’s series C increases to $260m, Avistone closes a $140m series B, OnCusp raises a $100m series A and HI-Bio grabs $95m in series B cash.

Financing Innovation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Hunter-Fleming
    • NeuroNova AB
    • Newron Pharmaceuticals SpA
UsernamePublicRestriction

Register